This book brings together recognized experts in the field to describe their current techniques for the surgical treatment of diseased thyroid, parathyroid, and adrenal glands, as well as neuroendocrine tumors of small bowel, pancreas, liver, and skin. For each procedure, indications, operative steps, potential pitfalls and complications, and postoperative management are presented. The clear descriptions coupled with informative and beautiful illustrations will give the reader new perspectives and insights into the anatomy and conduct of these procedures. Endocrine surgery has been an area of special interest to surgeons for well over a century, while the increasing incidence of neuroendocrine tumors has more recently led to greater attention to these neoplasms. Significant advances have been made in a variety of areas, the most recent being the introduction of minimally invasive methods of removing diseased glands, and the improved understanding of the natural history of neuroendocrine tumors.

"Lung Cancer: A Multidisciplinary Approach" provides clinicians with a comprehensive text that can be used when caring for patients with lung cancer throughout the entire patient journey. This edited collection explores the aetiology of lung cancer; mesothelioma; the range of available treatments, including chemotherapy and radiotherapy; surgical care; supportive and end-of-life care; quality-of-life issues; and the role of the nurse within the multidisciplinary team.A comprehensive, evidence-based guide to lung cancerIllustrative case studies used throughoutContributions from respected healthcare professionals in the fieldInterprofessional in focus

"Lung Cancer: A Multidisciplinary Approach" is an essential resource for all nurses and healthcare professionals working with cancer patients.

Bridging the gap between research and clinical application, Biosensors and Molecular Technologies for Cancer Diagnostics explores the use of biosensors as effective alternatives to the current standard methods in cancer diagnosis and detection. It describes the major aspects involved in detecting and diagnosing cancer as well as the basic elements of biosensors and their applications in detection and diagnostics.

The book addresses cancer molecular diagnostics, including genomic and proteomic approaches, from the perspective of biosensors and biodetection. It explains how to measure and understand molecular markers using biosensors and discusses the medical advantages of rapid and accurate cancer diagnostics. It also describes optical, electrochemical, and optomechanical biosensor technologies, with a focus on cancer analysis and the clinical utility of these technologies for cancer detection, diagnostics, prognostics, and treatment.

Making biosensor technology more accessible to molecular biologists, oncologists, pathologists, and engineers, this volume advances the integration of this technology into mainstream clinical practice. Through its in-depth coverage of a range of biosensors, the book shows how they can play instrumental roles in the early molecular diagnosis of cancer.

Winner of the Pulitzer Prize, and now a documentary from Ken Burns on PBS, The Emperor of All Maladies is a magnificent, profoundly humane "biography" of cancer--from its first documented appearances thousands of years ago through the epic battles in the twentieth century to cure, control, and conquer it to a radical new understanding of its essence. Physician, researcher, and award-winning science writer, Siddhartha Mukherjee examines cancer with a cellular biologist's precision, a historian's perspective, and a biographer's passion. The result is an astonishingly lucid and eloquent chronicle of a disease humans have lived with--and perished from--for more than five thousand years. The story of cancer is a story of human ingenuity, resilience, and perseverance, but also of hubris, paternalism, and misperception. Mukherjee recounts centuries of discoveries, setbacks, victories, and deaths, told through the eyes of his predecessors and peers, training their wits against an infinitely resourceful adversary that, just three decades ago, was thought to be easily vanquished in an all-out "war against cancer." The book reads like a literary thriller with cancer as the protagonist. From the Persian Queen Atossa, whose Greek slave may have cut off her diseased breast, to the nineteenth-century recipients of primitive radiation and chemotherapy to Mukherjee's own leukemia patient, Carla, The Emperor of All Maladies is about the people who have soldiered through fiercely demanding regimens in order to survive--and to increase our understanding of this iconic disease. Riveting, urgent, and surprising, The Emperor of All Maladies provides a fascinating glimpse into the future of cancer treatments. It is an illuminating book that provides hope and clarity to those seeking to demystify cancer.

Systems biology combines computational and experimental approaches to analyze complex biological systems and focuses on understanding functional activities from a systems-wide perspective. It provides an iterative process of experimental measurements, data analysis, and computational simulation to model biological behavior. This book provides explained protocols for high-throughput experiments and computational analysis procedures central to cancer systems biology research and education. Readers will learn how to generate and analyze high-throughput data, therapeutic target protein structure modeling and docking simulation for drug discovery. This is the first practical guide for students and scientists who wish to become systems biologists or utilize the approach for cancer research.

The accessible guide to the principles behind new, more targeted drug treatments for cancer Written for anyone who encounters cancer patients, cancer data or cancer terminology, but have no more than a passing knowledge of cell biology. A Beginner's Guide to Targeted Cancer Treatments provides an understanding of how cancer works and the many new treatments available. Using over 100 original illustrations, this accessible handbook covers the biology and mechanisms behind a huge range of targeted drug treatments, including many new immunotherapies. Dr Vickers translates a complex and often overwhelming topic into something digestible and easily understood. She also explains what cancer is, how it behaves and how our understanding of cancer has changed in recent years. Each chapter takes the reader through how new cancer drugs work and their benefits and limitations. With the help of this book, readers will be able to better understand more complex, in-depth articles in journals and books and develop their knowledge. This vital resource: Offers the latest insights into cancer biology Provides a broad understanding of how targeted cancer treatments work Describes many of the new immunotherapy approaches to cancer treatment, such as checkpoint inhibitors and CAR-modified T cells Helps readers feel confident discussing treatment options with colleagues and patients Provides an overview of which treatments are relevant to each of the most common solid tumours and haematological cancers, and the rationale behind them Demystifies the jargon - terms such as the EMT, cancer stem cells, monoclonal antibodies, kinase inhibitors, angiogenesis inhibitors etc. Explains the resistance mechanisms to many new treatments, including issues such as the way cancer cells diversify and evolve and the complex environment in which they live

: This issue of Emerging Cancer Therapeutics provides a comprehensive review for practitioners on the current status of melanoma treatment. Due to recent drug approvals and increasing ability to offer combined agents, there are many more treatment options available to melanoma patients than even a few years ago. Especially significant are the recent FDA approval of the immunotherapeutic agent ipilimumab for metastatic melanoma, and new agents targeting the BRAF gene in malignant melanoma. There is also coverage of the most recent data pertaining to surgical management, staging and prevention, and melanoma in children. Emerging Cancer Therapeutics provides a thorough analysis of key clinical research related to cancer therapeutics, including a discussion and assessment of current evidence, current clinical best practice, and likely near future developments. There is an emphasis throughout on multidisciplinary approaches to the specialty, as well as on quality and outcomes analysis. Emerging Cancer Therapeutics provides authoritative, thorough assessments of advances in therapeutics in all major areas of oncology, both solid and hematologic malignancies, with a focus on advances in medical and biological therapies with emerging clinical impact and encompassing new technologies with implications for management such as molecular imaging.

Pancreatic Cancer, Cystic Neoplasms and Endocrine Tumors: Diagnosis and Management is a modern, expertly crafted and clinically focused guide to the diagnosis, management and best-practice care of patients suffering from pancreatic cancer, cystic neoplasms and endocrine tumours. Packed with outstanding figures and with reference to the leading society guidelines, its main focus is on the many endoscopic and radiologic diagnostic techniques, medical and surgical management of both full-blown cancer and other tumors, and the risks of each form of treatment. Also covered in detail are issues of tumor recurrence and long-term outcome of treatment. Brought to you by highly skilled national and international leaders in the specialty and an experienced editor team, this is an invaluable guide to practicing gastroenterologists and surgeons in the hospital and clinical environment, as well as oncologists and endocrinologists managing patients with pancreatic tumorous lesions.

The feminist women's health movement of the 1960s and 1970s is credited with creating significant changes in the healthcare industry and bringing women's health issues to public attention. Decades later, women's health issues are more visible than ever before, but that visibility is made possible by a process of depoliticization The Vulnerable Empowered Woman assesses the state of women's healthcare today by analyzing popular media representations-television, print newspapers, websites, advertisements, blogs, and memoirs-in order to understand the ways in which breast cancer, postpartum depression, and cervical cancer are discussed in American public life. From narratives about prophylactic mastectomies to young girls receiving a vaccine for sexually transmitted disease, the representations of women's health today form a single restrictive identity: the vulnerable empowered woman. This identity defuses feminist notions of collective empowerment and social change by drawing from both postfeminist and neoliberal ideologies. The woman is vulnerable because of her very femininity and is empowered not to change the world, but to choose from among a limited set of medical treatments. The media's depiction of the vulnerable empowered woman's relationship with biomedicine promotes traditional gender roles and affirms women's unquestioning reliance on medical science for empowerment. The book concludes with a call to repoliticize women's health through narratives that can help us imagine women-and their relationship to medicine-differently.

This book is a guide for individuals who need to support patients with advanced cancer. It discusses treatment options such as palliative care, clinical trials, hospice care, and home care, as well as symptom control. It also addresses emotional concerns including feelings, communicating with friends and family, and living life to its fullest and with meaning. Lists of federal and non-profit organisations are provided that may be helpful in giving information and services to cancer patients. This book also explores many of the questions and crossroads that face caregivers when their loved one has been told that he or she has advanced cancer that is no longer responding to treatment.

The best and most concise single source for state-of-the-art diagnosis and treatment of lung cancer -newly revised, updated, and expanded.Lung cancer has long been the number-one cause of death from cancer every year and the third most frequently diagnosed after breast and prostate cancers. In 2010, about 15% of all cancer diagnoses and 30% of all cancer deaths were due to lung cancer. Needless to say, there is a great need for more rapid advancements in diagnosis and treatment of this devastating disease.

Here is the comprehensively revised, updated, and expanded edition of the well-established, evidence-based reference book that deals with the most recent advances in lung cancer prevention, screening, diagnosis, research, and treatment for the clinician. Edited and authored by leading authorities in the field, this Fourth Edition of the highly regarded" Lung Cancer" is better than ever -featuring nine new chapters along with seven re-formatted ones that are nearly brand new in content and approach. It covers Smoking Prevention and Cessation; Molecular Profiling; Somatic Genome Alterations in Human Lung Cancers; Management of Multi-Focal Bronchioloalveolar Carcinoma (BAC); Primary Tracheal Tumors; Predictive Tumor Biomarkers for EGFR Inhibitors; Non-Small Cell and Small-Cell Lung Carcinoma; and more.

This Fourth Edition of "Lung Cancer" Provides the very latest research in the identification of biomarkers to predict a high risk for developing lung cancer - vital for implementing screening, diagnosis, and prevention strategiesPresents the newest lung cancer staging system, as well as updated and cutting-edge surgical and radiation therapy techniques that make local tumor control more effective and less invasive while sparing normal tissuesDiscusses combined modality therapy and new chemotherapeutic agents which are yielding higher response rates and improved survival when used in the adjuvant setting or concurrent with highly sophisticated radiation or proton treatmentOffers novel and emergent approaches to preventative, diagnostic, and therapeutic modalities with an emphasis on the best evidence available from the latest studies and clinical trials

With almost half of the revised and updated content being brand new, "Lung Cancer," Fourth Edition, is an important and vital resource for all medical professionals and students involved in the care and treatment of those struck with this catastrophic illness.

In this book, experts in the field express their well-reasoned opinions on a spectrum of important and complex issues in the area of cord blood transplantation. The aim is to provide practicing hematologists, including hematopoietic transplant physicians, with clinically relevant and immediately applicable information that will assist in the delivery of optimal care. The book opens by offering a historical perspective and examining current concepts and practices in cord blood banking. Sections are then devoted to strategies for cord blood graft selection and to areas of consensus and controversy in cord blood transplantation for neoplastic diseases - and nonmalignant - in children and adults. Attention is drawn to the implications of high-impact clinical trials whenever such trials are available. The readily intelligible text is complemented by numerous helpful tables, algorithms, and figures. This book will appeal to all residents, fellows, and faculty members responsible for the care of hematopoietic cell transplant patients and will offer a robust, engaging tool to aid vital activities in the daily work of every hematology and oncology trainee.

The goal of this volume is to comprehensively cover a highly readable overview on our present knowledge of the role of Notch signalling for embryology and cancer, with a focus on new findings in molecular biology. Topics that are discussed in-depth by leading researchers and clinicians range from the newest findings in cellular and molecular pathology to new concepts for prophylaxis and treatment of cancer. Experts in the field as well as scientists and health care professionals not intimately involved in these specialized areas are provided with the most significant and timely information related to these topics. It is the aim of this book to summarize essential up-to-date information for every clinician or scientist interested in the role of Notch signalling in embryology and cancer. We hope that this volume will be adopted as the standard text in this area of science and will stimulate new interest in the role of Notch signalling for embryology and cancer. We further hope that this compendium will serve as both a source for current researchers and a guide to stimulate and assist those in related disciplines to enter this exciting field of research.

This comprehensive and authoritative reference covers all aspects of the group of disorders collectively known as the lymphoid neoplasms. The reader is taken through a description of its normal cellular origins and the molecular genetic abnormalities that can lead to this group of conditions, a section of the book that has been considerably strengthened for this third edition, to the environmental factors that may be relevant to disease development, and, finally, to the pragmatic aspects of disease management. The authors synthesise for the reader apsects of current knowledge and likely future developments, and direct them to the appropriate resources should they wish to pursue particular avenues of scientific or literature research.

This special topic issue of 'Visceral Medicine' contains contributions discussing the subject in-depth. 'Visceral Medicine' is a well-respected, international peer-reviewed journal in surgery. Special topic issues are included in the subscription.

This book explores topics of importance to all who have an interest in economic methods for assessment of the efficacy and effectiveness of new cancer treatments and in regulatory measures relating to their marketing authorization and pricing. Targeted therapies and modern immunotherapy are placing a substantial strain on health care budgets. Regulation and economic methods to assess the parameters for establishing efficacy and effectiveness are therefore of prime importance. Payer authorities have to determine whether the use of these novel therapies yields clinical benefits that justify their increasing cost. In the simplest terms, cost-effectiveness analyses quantify the ratio between the extent to which an intervention raises healthcare costs and the extent to which it improves health outcomes. Rigorous cost-effectiveness analyses translate all health outcomes into quality-adjusted life years. On the other hand, in order to sustain innovation, price regulations must be coupled with efforts to ensure that drug companies are still able to recoup their investments in high-risk and high-costs research programs. Ultimately, decisions regarding health care expenditures are also a question of society's willingness to pay.

Since the year 2000, exciting developments in cancer therapy have occurred. For decades in the 20th century, the hallmark of medical treatment for cancer had been cytotoxic chemotherapy, with drugs targeting rapidly dividing cells, including cancer cells but also certain normal tissues. As a result, many patients experienced the "classic" toxicities of alopecia, gastrointestinal symptoms and/or myelosuppression. In the last years, however, clinical research has been strongly occupied with the identification of mutations and aberrations concerning molecular pathways in cancer and their alterations, which has enabled the emergence of a "targeted" (somewhat personalized) medicine approach to treatment. Today, although traditional cytotoxic chemotherapy remains the treatment of choice for many malignancies, notably as first-line agents, targeted therapies are a possible choice for many types of cancer, including breast, prostate, CRC, lung, kidney cancers, as well as lymphoma, leukaemia, and myeloma. Over 60 of these targeted therapies recently approved by the United States Food and Drug Administration (FDA) are detailed in the book, and their intended use in one or more cancer types are shown.

Clinical Oncology and Error Reduction fills a gap - the lack of a single volume on medical error in the vast field of cancer care - that has existed since a 1999 Institute of Medicine's report introduced the term `medical error' as a topic for doctors and patients alike. The volume, edited by Antonella Surbone, M.D., a clinical oncologist and Michael Rowe, Ph.D., a medical sociologist, includes chapters written by experts on the topic including physicians, nurses, patients, and advocates, and covers a wide range of topics essential to an understanding of the unique character, challenges, and needed responses to the risk, incidence, and aftermath of medical error in the diagnosis, treatment, and aftermath of treatment for cancer. Clinical Oncology and Error Reduction will serve as the standard for framing the discussion of error in the field for oncologists, epidemiologists, nurses, healthcare administrators, researchers, and scholars. An indispensable handbook for all clinical oncologists, their staff, nurses, and oncology residents and fellows, this book: Contains practical information for immediate clinical application Covers topics such as patient safety, error prevention, quality improvement, errors disclosure and apology, and the impact of errors on patients and doctors Each chapter contains special "take home" points that highlight issues of particular clinical relevance and application Prepared by an expert, multidisciplinary, international team of physicians, nurses, researchers, hospital administrators, bioethicists, patients and patient advocates Dr. Surbone shared with ASCO Connection her insights about patient safety and medical errors and offered a glimpse into the history that led to this new book: https://connection.asco.org/magazine/features/opening-dialogue-about-medical-errors

This new atlas represents a fresh fresh approach to cardiac anatomy, providing images of unparalleled quality, along with explanatory text, to show in vivo heart anatomy and explain the clinically relevant underlying anatomic concepts. In spite of amazing proliferation of information on the Internet and multiple websites filled with up-to-date information, there is no similarly detailed and systematic compilation of morphological imaging with CT. Organized for both systematic learning and to serve as a quick, yet detailed reference for specific clinical questions, this book is an invaluable resource for medical students and residents, cardiologists, and especially surgeons, interventionalists and electrophysiologists, who depend on ever more detailed imaging support in order to successfully perform increasingly complex coronary and noncoronary structural interventions and other procedures.

The book discusses a vital problem of diagnostics and treatment of peritoneal malignancies, pseudomyxoma and malignant mesothelioma, which is still insufficiently developed. Compared to similar, earlier editions, this volume importantly presents cutting-edge approaches and up-to-date diagnostic methods.The authors place special emphasis on morphological/pathological characteristics of these tumors involving immunodiagnostic techniques, and a chapter on the immunotherapy of mesothelioma and pseudomyxoma will be of special interest to readers.Fully illustrated, the book will present an algorithm of diagnostics and complex treatment of these tumors.

Drs. Eduardo D. Bruera and Russell K. Portenoy have completely revised and updated the widely respected Cancer Pain: Assessment and Management for the second edition of this unanimously praised book. This is a comprehensive, clinically oriented review of all aspects of the complex and multidimensional problem of cancer pain. The unique characteristics of cancer pain, including pathophysiology, clinical assessment, diagnosis, and pharmacological and nonpharmacological management are all discussed here in detail. Internationally recognized leaders in cancer pain research have contributed to many new chapters, including neuraxial analgesia, hospice and institution-based palliative care programs, bone pain, and cancer pain and palliative care in the developing world. Cancer Pain continues to be a scholarly but accessible text that is an essential resource for physicians, nurses, and medical students who treat suffering from cancer pain. Per the New England Journal of Medicine, This book should be in the library of every physician who comes into contact with patients with pain. It is truly superb.

Cancer is the second leading cause of morbidity and mortality worldwide, ranking just after cardiovascular diseases. In the central nervous system, gliomas constitute the most frequent type of tumors. According to the definition, oligodendrogliomas are diffusely infiltrating glial tumors, composed of neoplastic oligodendroglial cells, typically found in cerebral hemispheres in adult population, although not uncommon in children. They encompass a range of tumours, from well-differentiated to frankly malignant neoplasms. In the current World Health Organization (WHO) classification of tumors of the central nervous system, covering a four-tiered WHO grading scheme, oligodendrogliomas are recognised as grade WHO II and WHO III by the degree of malignancy. They may be either well differentiated, composed of neoplastic cells that morphologically resemble oligodendroglia, or may harbor focal or diffuse features of malignancy, respectively. Their prognosis is in this case less favorable. This book provides current research on the diagnosis, outcomes and prognosis of oligodendrogliomas. Chapter one examines the pathology, molecular mechanisms and clinical references of ODs. Chapter two discusses the ODs and the problematic diagnostic markers. Chapter three examines the histopathologic features of oligodendrogliomas and of an assortment of other central nervous system neoplasms that can resemble them and reviews features that allow one to sort through these histopathologic differential diagnoses. The final chapter reviews speech mapping in oligodendroglioma operations and provides data regarding patient outcomes with these methods.

When her new-born daughter Charlotte was diagnosed with a rare and deadly leukaemia, Pia de Jong and her husband made a momentous decision: they rejected chemotherapy and instead choose to "wait for what will come". As the following year unfolded, they entered a disorienting world of doctors, medical procedures, and a cast of neighbours and protectors in Amsterdam. de Jong's house became her inner sanctum, where she gave Charlotte the unfiltered love and strength she needed. Their decision, now known as "watchful waiting", has become the standard medical protocol for Charlotte's type of leukaemia. This deeply felt memoir reveals the galvanizing impact one child can have on a family, a neighbourhood and a worldwide medical community. Vivid and immersive, Saving Charlotte is also a portrait of a woman's brave voyage of love, hope and, in its inspiring climax, self-discovery.